EyePoint Pharma Q3 loss widens

EyePoint

05/11/2025 12:26

Overview

EyePoint Q3 2025 net revenue declines to $1.0 mln from $10.5 mln in Q3 2024

Net loss widens to $59.7 mln in Q3 2025, driven by increased clinical trial costs

Company raises $172.5 mln in oversubscribed equity financing, extending cash runway into Q4 2027

Outlook

EyePoint expects cash to fund operations into Q4 2027

Company anticipates DURAVYU Phase 3 data readout in mid-2026

First patient dosing for DME trials expected in Q1 2026

Result Drivers

CLINICAL TRIAL COSTS - Increased costs from DURAVYU Phase 3 trials for wet AMD drove higher operating expenses

OPERATING EXPENSES - For the third quarter ended September 30, 2025, totaled $63.0 million versus $43.3 million in the prior year period

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Sales
$582,000
Q3 Net Income
-$59.73 mln
Q3 Basic EPS
-$0.85
Q3 Operating Expenses
$62.99 mln
Q3 Operating Income
-$62.02 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for EyePoint Pharmaceuticals Inc is $29.50, about 58% above its November 4 closing price of $12.39

Press Release: ID:nGNX8GVGZY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)